Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in ...
Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes and chronic kidney disease have a 24% lower risk for kidney disease progression and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results